Increasing the Accuracy of In Vivo Models for Oncolytic Adenovirus Vectors with a Syrian Hamster Model
SLU ID 03-016 | Syrian Hamster Model for Oncolytic Adenovirus Vectors
Intellectual Property Status
Seeking
Proprietary non-patented intellectual property
Know-how based
Tangible material
Licensees
Development partner
Commercial partner
Investment
University spin out company
Background
Using genetically modified replication-competent (i.e., oncolytic) adenovirus vectors to infect cancer cells and destroy them while having acceptable toxicity in normal tissue is a potential approach to treating cancer. Most studies in this field have investigated the efficiency of these vectors in immunodeficient mice bearing human tumor xenografts. However, this model doesn't fully address the situation in human cancer patients being treated with oncolytic adenovirus because the mouse is immunodeficient as well as non-permissive or semi-permissive for replication of human adenoviruses.
Overview
Researchers at Saint Louis University have developed a Syrian hamster model to enable the evaluation of the safety and efficacy of oncolytic adenovirus vectors for treating cancers and other diseases.
Benefits
The potential advantages of this technology over existing solutions include:
Increase the accuracy of in vivo models used to test the safety and efficacy of oncolytic adenovirus vectors
Minimize the cost of testing the safety and efficacy of oncolytic adenovirus vectors
Applications
Potential applications of this technology include:
Cancer research
Drug development
Opportunity
Saint Louis University offers non-exclusive licenses for this technology.